AWM
PMCB icon

Abound Wealth Management’s PharmaCyte Biotech PMCB Stock Holding History

Abound Wealth Management’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$1 – 1517
2026
Q1 		$1 Buy
+1
New +$1 ﹤0.01% 1492

Other funds holding PMCB

EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
BL
BFSG LLC Irvine, California $1.13B AUM 29.95% 1-Year Est. Return

Abound Wealth Management's PMCB Position: Q2 2026 in Review

Abound Wealth Management sold out of PharmaCyte Biotech (PMCB) in Q2 2026, closing a stake of 1 share — an estimated $1 sold.

Abound Wealth Management first reported a position in PMCB in Q1 2026 and held it in 1 quarter. The position peaked at $1 in Q1 2026. 3 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Abound Wealth Management reported no remaining PharmaCyte Biotech position as of Q2 2026 after selling out during the quarter.
  • Abound Wealth Management sold 1 PharmaCyte Biotech share in Q2 2026, an estimated $1.
  • Abound Wealth Management first reported a position in PharmaCyte Biotech in Q1 2026 and held it in 1 quarter.
  • Abound Wealth Management's PharmaCyte Biotech position peaked at $1 in Q1 2026.
  • 3 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.